News from the BioRN Cluster

Home  >>  News from the BioRN Cluster

Roche: FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis

On Mai 23, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Roche: FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis

Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and…

DKFZ: Tailor-made viruses for enhanced cancer therapy

On Mai 21, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für DKFZ: Tailor-made viruses for enhanced cancer therapy

Scientists collaborating in a new bi-national research unit that was officially inaugurated on May 2 in Luxemburg aim to develop a second-generation viral therapy for cancer. The two partners in the new alliance are the German Cancer Research Center (DKFZ) in Heidelberg and the Luxembourg Institute of Health (LIH). The…

DKFZ: Stop signal for dangerous immune responses

On Mai 19, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für DKFZ: Stop signal for dangerous immune responses

Scientists from the German Cancer Research Center (DKFZ) have copied a trick that dying cells use to prevent an undesired immune response. They now plan to develop this biological principle into a therapy method that specifically blocks allergic reactions or autoimmune responses without suppressing the whole immune system. The Federal…

DKFZ: Defective intercellular connections cause hydrocephalus

On Mai 17, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für DKFZ: Defective intercellular connections cause hydrocephalus

A defective gene leads to changes in the cellular layer between cerebrospinal fluid and brain nervous tissue, thus causing a buildup of fluid in the brain. This link, which scientists from the German Cancer Research Center in Heidelberg have now discovered, is the first known mechanism underlying genetic hydrocephalus. About…

Boehringer Ingelheim: Boehringer Ingelheim Inaugurates World-Class Biopharmaceutical Manufacturing Facility in China

On Mai 17, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Boehringer Ingelheim: Boehringer Ingelheim Inaugurates World-Class Biopharmaceutical Manufacturing Facility in China

Ingelheim, Germany, and Shanghai, China, 16 May 2017 –Today, Boehringer Ingelheim inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China). The site, with the first-phase investment of more than €70 million, is the first and only biopharmaceutical facility established by a leading multinational active…

EMBL: Cell changes drive breast cancer relapse

On Mai 16, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für EMBL: Cell changes drive breast cancer relapse

Researchers identify features of residual breast cancer cells that suggest new approaches for preventing relapse In organoid cultures, mouse residual breast cancer cells (right) have elevated lipid metabolism (green). IMAGE: Jechlinger/EMBL Relapse is now the main cause of death for breast cancer patients. Researchers at EMBL have found that, in…

EMBL-EBI: HipSci,The human stem cell bank

On Mai 15, 2017, Posted by , In News,Press Releases, With Kommentare deaktiviert für EMBL-EBI: HipSci,The human stem cell bank

UK’s largest resource of human stem cells from healthy donors unveiled Stem cell researchers have produced one of the largest collections of high-quality human induced pluripotent stem cell lines (iPSCs) from healthy individuals. This comes as result of a close collaboration between the European Bioinformatics Institute (EMBL-EBI), the Wellcome Trust…

TICEBA: TICEBA exclusively licenses ABCB5+ technology for treatment of ocular and dermal diseases

On Mai 15, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für TICEBA: TICEBA exclusively licenses ABCB5+ technology for treatment of ocular and dermal diseases

TICEBA GmbH expanded an exclusive license agreement with Boston Children’s to include the treatment of ocular and dermal diseases by targeting ABCB5, a cell-surface marker found on stem cells, developed by Markus Frank, MD, in the division of Nephrology Research. In collaborations with Schepens Eye Research Institute and the US…

Fraunhofer IGB: Nose2Brain – Better Therapy for Multiple Sclerosis

On Mai 12, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Fraunhofer IGB: Nose2Brain – Better Therapy for Multiple Sclerosis

Over the next few years, in a research project funded by the EU, an international consortium is developing a new technology for a better treatment of multiple sclerosis. The idea of the innovative “Nose2Brain” approach is to transport a special active substance directly through the nose into the central nervous…

Merck: FDA Grants Bavencio® (avelumab) Approval for a Common Type of Advanced Bladder Cancer

On Mai 10, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Merck: FDA Grants Bavencio® (avelumab) Approval for a Common Type of Advanced Bladder Cancer

Second approval for Bavencio in less than two months Advanced urothelial carcinoma is an aggressive disease with a high rate of recurrence Darmstadt, Germany, and New York, US, May 9, 2017 – Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved…

VAXIMM: VAXIMMM kündigt Kollaboration mit Merck und Pfizer zur Untersuchung der Kombination von VXM01 und Avelumab im Glioblastom und Darmkrebs in klinischen Phase-I/II-Studien an

On Mai 9, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für VAXIMM: VAXIMMM kündigt Kollaboration mit Merck und Pfizer zur Untersuchung der Kombination von VXM01 und Avelumab im Glioblastom und Darmkrebs in klinischen Phase-I/II-Studien an

Basel (Schweiz) und Mannheim (Deutschland), 9. Mai 2017 – Die VAXIMM AG, ein schweizerisch/deutsches Biotechnologieunternehmen, das auf die Entwicklung oraler T-Zell-Immuntherapien spezialisiert ist, gab heute eine Kollaborationsvereinbarung mit Merck (MRK), einem führenden Wissenschafts- und Technologieunternehmen, und Pfizer Inc. (NYSE: PFE) bekannt. Gegenstand der Zusammenarbeit ist die Kombination von Avelumab[1], einem…

Roche: Roche launches AVENIO ctDNA Analysis Kits for Oncology Research

On Mai 9, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Roche: Roche launches AVENIO ctDNA Analysis Kits for Oncology Research

First blood-based distributed oncology tests covering all four mutation classes Three test choices provide accurate insights into different stages and types of cancer Streamlined testing generates results in five days Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global commercial launch of the AVENIO circulating tumor DNA (ctDNA) Analysis Kits,…

Novaliq: NOVALIQ Conducts A First-in-class OCULAR NEUROPATHIC PAIN AND ANTI-INFLAMMATORY CANNABINOID DRUG DEVELOPMENT PROGRAM IN COLLABORATION WITH THE UNIVERSITY OF COLOGNE, GERMANY

On Mai 9, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Novaliq: NOVALIQ Conducts A First-in-class OCULAR NEUROPATHIC PAIN AND ANTI-INFLAMMATORY CANNABINOID DRUG DEVELOPMENT PROGRAM IN COLLABORATION WITH THE UNIVERSITY OF COLOGNE, GERMANY

Heidelberg, Germany –May 8, 2017 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced successful application of a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid-based dry eye disease (DED) treatment approach in collaboration with…

EMBL: EMBL spin-off company Luxendo acquired by Bruker

On Mai 9, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für EMBL: EMBL spin-off company Luxendo acquired by Bruker

Accelerating researchers’ access to next-generation light-sheet microscopy EMBL spin-off company Luxendo has been acquired by the Bruker Corporation. Based in Heidelberg, Germany, Luxendo develops and commercialises microscopes that use the Single Plane Illumination Microscopy (SPIM) technique developed by EMBL researchers. “It has been very rewarding to witness the rapid trajectory…

DKFZ/HI-STEM: Vitamin A deficiency is detrimental to blood stem cells

On Mai 9, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für DKFZ/HI-STEM: Vitamin A deficiency is detrimental to blood stem cells

Lack of vitamin A in the body has a detrimental effect on the hematopoietic system in the bone marrow. The deficiency causes a loss of important blood stem cells, scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute of Stem Cell Research and Experimental Medicine (HI-STEM) now…

Die Behandlung chronischer Krankheiten nachhaltig verändern! Das Handwerkszeug für mein eigenes Startup erlernen!

On Mai 5, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für Die Behandlung chronischer Krankheiten nachhaltig verändern! Das Handwerkszeug für mein eigenes Startup erlernen!

Die EITHealth Summer School euVENTION macht genau dies möglich. In einem strukturierten zweiwöchigen Programm erarbeiten Sie anhand einer realen Herausforderung, aus Industrie und Akademia, Lösungen, die mit einem eigenen Startup umgesetzt werden können. Dazu nutzen Sie aktuelle Innovationsmethoden, wie Design Thinking, Rapid Prototyping und Business Model Innovation. Die Teilnahme an…

EMBL: Hungary becomes EMBL member state

On Mai 2, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für EMBL: Hungary becomes EMBL member state

EMBL welcomes its 23rd member state, with a promising collaboration already in place On 20 April EMBL welcomed Hungary as its 23rd member state, highlighting EMBL’s commitment to promoting international science and forming close ties with researchers across Europe. “This is an important step for EMBL, and for life science…

Springer: Springer Nature startet zwei neue ORCID-Initiativen

On Mai 2, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Springer: Springer Nature startet zwei neue ORCID-Initiativen

In einem Testlauf verpflichtet Springer Nature ab sofort Autoren von 46 wissenschaftlichen Zeitschriften zur Nennung einer ORCID iD Berlin, 28. April 2017 Mit zwei Initiativen fördert Springer Nature erneut die Nutzung von ORCID, einer Organisation, die Wissenschaftlern numerische Codes zuteilt, über die diese dann eindeutig identifiziert werden können. Die ORCID…

EMBL: Illuminating insulin release

On Mai 2, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für EMBL: Illuminating insulin release

EMBL researchers develop an optical method for measuring the release of insulin from single cells Typical laboratory tests to measure levels of insulin – the hormone that controls our blood sugar – are based on the total amount of insulin secreted by a large number of cells. But exploring the…

Merck: Merck Divests Biosimilars Business to Fresenius

On Mai 2, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für Merck: Merck Divests Biosimilars Business to Fresenius

Darmstadt, Germany, April 24, 2017 – Merck, a leading science and technology company, today announced the divestment of its Biosimilars business to Fresenius. The decision to divest Biosimilars is aligned with Merck’s strategy for its Healthcare business sector to focus on its pipeline of innovative medicines. According to the terms…